After the Supreme Court’s reversal of IEEPA tariffs, a new combination of Section 232 and Section 301 tariffs is rapidly reshaping the trade landscape for US importers. Legal and trade advisers at
The Court of Appeal has issued a significant ruling in Geeks Ltd v Watts [2026] EWCA Civ 889, surprising many employment law practitioners across the UK. The decision examined whether training repayment
More
The Texas Senate race has found an unlikely arena for its sharpest political commentary, with a comedy podcast cutting through where traditional media has hesitated. Ron White, the scotch-in-hand veteran of the
More
American Savings Bank, trading under the ticker ASB on the New York Stock Exchange, made a strong first impression as shares jumped more than 6% on its trading debut. The bank’s opening
More
Pets at Home Group (PETS), one of the UK’s largest specialist pet care retailers, has seen its share price fall by 59%, raising questions about whether the stock now offers value for
More
Automated cell therapy manufacturing specialist Cellares is joining forces with Taiwanese biotech GenomeFrontier Therapeutics to advance virus-free CAR-T production. The partnership will assess whether GenomeFrontier’s virus-free manufacturing process is compatible with Cellares’
More
Growth equity has established itself as one of the most resilient corners of private markets, drawing significant capital even as other strategies struggle with expensive debt and cautious lenders. Funds focused on
More
The Federal Circuit suspended Judge Pauline Newman from hearing cases in 2023, and that order has been renewed every year since, with a fourth renewal window now open. Judge Newman is 99
More
Among the fastest-growing sectors in global markets, artificial intelligence applied to healthcare continues to attract significant institutional and retail investor attention in 2026. The convergence of machine learning, diagnostics, drug discovery, and
More
The FTSE 250 index is home to dozens of income-generating stocks, but few manage to combine a high yield with genuine prospects for future dividend growth. A 6% dividend yield stands well
More
AstraZeneca (AZN) and Daiichi Sankyo have secured a significant victory after their flagship antibody drug conjugate Enhertu was approved for NHS use in England and Wales. The drug value assessor for England
More